Will DTC Advertising Appear In Europe? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Will DTC Advertising Appear In Europe?
Direct-to-consumer (DTC) advertising is firmly entrenched in the US, but has historically been considered as an inappropriate means of communication in Europe for prescription-only medicines. With European patients demanding more information on medicines, coupled with potential new legislation, will DTC finally gain a foothold in Europe?


Pharmaceutical Technology Europe
Volume 23, Issue 1

Part of the reason could be because ideas around DTC have not been raised in isolation and make up the so-called "pharmaceutical package" currently being discussed at EU level.8 The package includes measures for tackling counterfeit medicines and improving pharmacovigilance, which have been widely welcomed. However, it also includes measures for disseminating information to patients, which has alarmed opponents of DTC.

However, the driving force for these changes is patients, who feel that they still have difficulties in accessing medicines' information. In their minds, the focus for policy change is on the provision of information rather than promotion. It is widely agreed that information on medicines in Europe is fragmented, which puts patients at a disadvantage in receiving healthcare.9

At present, Article 88 of Directive 2001/83/EC — a set of rules for pharmaceutical advertising — prohibits DTC advertising of prescription-only medicines, but interpretations of the directive can vary between EU member states.9 Presumably, those who back a revision to the way information is communicated in Europe believe some sort of standardisation is needed and that some aspects of DTC could be acceptable if they benefit the patient.

The lack of clarity over what is being proposed for Europe has caused a number of delays with the EC's Directive on Information to Patients. In November 2010, some progress was made with potential promotional routes for information being specifically rejected;9 MEPs backed measures to ban information on prescription drugs being made available on radio and television, and also extended the ban to print media. At the first reading of the legislation, MEPs supported the provision of "objective information on a drug's characteristics and the treated disease or condition", but rejected "unsolicited information or disguised advertising".8

What the current legislation does acknowledge is that pharma companies know their products best. In line with this, the legislation will allow companies to provide basic information on product characteristics, labelling and package leaflets, as well as an accessible version of a drug's assessment report. However, it will be up to individual member states whether or not to extend this to include other non-promotional information, such as pricing details and packaging changes.

Providing more information may enhance the role that European patients play in healthcare. For example, there are hopes that, by being better informed, patients will be able to contribute towards pharmacovigilance measures by reporting their adverse effects directly to national authorities.10 The European Parliament has introduced draft legislation to facilitate the introduction of specialised pharmaceutical portals that would contain an array of medical information on medicinal products and their proven side effects. These would also instruct patients on how to report adverse events using these sites and other means. The national portals will also be linked to EU ones so that information is not lost across the region. At the moment, one of the alleged weaknesses in the EU is that information on an adverse reaction at national level may not be recorded at a regional level, thereby not providing a full picture of a product's potential side effect profile.

Summary

In Europe, patient demand for increased access to information on medicines looks likely to result in pharma companies being permitted to directly communicate with patients. However, it is difficult to see DTC evolving into the advertising style typified by the US market, particularly as the European pharma industry itself has been careful to distance itself from such an approach. The culture and market conditions in Europe remain very different to those in the US and so it unlikely that DTC advertising would ever have a receptive audience.

References

1. European Public Health Alliance, "Direct-To-Consumer Advertising — for or against?" (2008). http://www.epha.org/

2. F. B. Palumbo and C.D. Mullins, Food and Drug Law Journal, 57(3), 423–443 (2002).

3. M.A. Gagnon and J. Lexchin, PloS Medicine (January, 2008).

4. P. Kelly, Health Affairs (April, 2004). http://content.healthaffairs.org/

5. GSK, "Direct-to-consumer advertising" (2010). http://www.gsk.com/

6. ABPI, "ABPI welcomes European Parliament decision on DTC" (2002). http://www.abpi.org.uk/

7. Inpharm, "DTC: the new philosopher's stone?" (2003). http://www.inpharm.com/

8. Scrip 100, Reform on the Agenda (2010). http://www.scrip100.com/

9. PharmaTimes, "MEPs vote for pharma to 'inform, not advertise'" (2010). http://www.pharmatimes.com/

10. European Parliament, "Protecting patients: EU to upgrade medicine safety monitoring. European Parliament" (2010). http://www.europarl.europa.eu/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here